Regulatory Compliance Update
Glenmark Pharmaceuticals Ltd has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its formulations manufacturing facility located in Goa, India. The inspection report has been classified with Voluntary Action Indicated (VAI) status, indicating that the facility meets regulatory compliance standards without requiring further regulatory action.
Inspection Details
The U.S. FDA inspection was conducted at the company's Goa manufacturing facility over a period of nine days, from June 22, 2026 to June 30, 2026. The VAI classification confirms that the facility maintains compliance with current Good Manufacturing Practice (cGMP) regulations and does not require any official FDA action.
Company Background Context
Glenmark Pharmaceuticals is described as a research-led, global pharmaceutical company with 11 world-class manufacturing facilities across four continents and six R&D centres. The company has a commercial footprint in over 80 countries and maintains a diversified portfolio across branded, innovative, generics, and consumer health products, with particular focus on respiratory, dermatology, and oncology therapeutic areas. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.
Disclosure Format
This announcement was filed as a regulatory disclosure to both the National Stock Exchange of India Limited and BSE Limited under reference number 57/26-27, signed by Rashmi Khandelwal, Company Secretary & Compliance Officer (ACS – 28839).